위암 치료 시장 예측(2026-2032년)

The Stomach Cancer Treatment Market is projected to grow by USD 12.79 billion at a CAGR of 11.16% by 2032.

Stomach cancer treatment is undergoing a decisive clinical and operational transition as healthcare systems respond to the continuing burden of gastric and gastroesophageal junction cancers. According to global cancer surveillance data, gastric cancer remains among the leading causes of cancer incidence and cancer-related mortality worldwide, with outcomes strongly influenced by stage at diagnosis and access to specialized care. Treatment pathways increasingly combine surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, endoscopic intervention, nutritional support, and palliative care within multidisciplinary oncology programs. Verified clinical guidance from major oncology bodies emphasizes biomarker-driven decision-making, including HER2 status, mismatch repair or microsatellite instability status, PD-L1 expression, and emerging molecular alterations that influence therapy selection. At the same time, earlier detection, perioperative optimization, symptom management, and survivorship care are becoming central to improving patient outcomes. The treatment landscape is shaped by disease stage at diagnosis, tumor location, histology, Helicobacter pylori-associated risk patterns, patient fitness, access to diagnostics, and availability of specialized surgical and systemic therapy services. As stakeholders seek more effective and equitable cancer care, the stomach cancer treatment ecosystem is advancing toward precision oncology, integrated diagnostics, evidence-based sequencing, and patient-centered management.

Transformative Shifts in the Stomach Cancer Treatment Landscape

The stomach cancer treatment landscape is being transformed by the movement from uniform treatment protocols toward individualized care based on tumor biology and patient-specific risk. Perioperative chemotherapy and gastrectomy with appropriate lymph node dissection remain foundational for resectable disease, while systemic therapy plays a central role in advanced and metastatic gastric cancer. Immunotherapy has altered treatment algorithms for selected patients, particularly where immune checkpoint inhibitors are supported by biomarker evidence and regulatory approval. Targeted therapy has also become increasingly important for HER2-positive disease and other molecularly defined subgroups, reinforcing the need for high-quality pathology and molecular testing at diagnosis. Minimally invasive and robotic-assisted surgical approaches are gaining clinical attention where expertise and infrastructure are available, while endoscopic resection is used for carefully selected early-stage lesions that meet established criteria. Supportive care is also becoming more structured, with greater attention to cachexia, anemia, dysphagia, pain, psychosocial support, treatment-related toxicity management, and patient-reported outcomes. These shifts are creating a more complex but more clinically responsive environment for stomach cancer care, where treatment value is increasingly measured by survival, functional recovery, quality of life, and continuity of care.

Cumulative Impact of Artificial Intelligence on Stomach Cancer Care

Artificial intelligence is increasingly influencing stomach cancer treatment across the care continuum, particularly in image interpretation, pathology review, treatment planning, and clinical workflow optimization. In endoscopy, AI-assisted detection tools are being studied and deployed to improve recognition of suspicious gastric lesions, support earlier diagnosis, and reduce variability between operators, especially in settings with structured screening or high endoscopy volumes. In radiology, machine learning models are being evaluated for tumor staging, treatment response assessment, lymph node evaluation, and recurrence-risk prediction using imaging features. Digital pathology and computational analysis can support evaluation of histologic patterns and biomarker expression, although clinical deployment still requires external validation, quality control, interoperability, and regulatory oversight. AI is also being applied to integrate electronic health records, molecular profiles, laboratory data, imaging results, and clinical notes to support multidisciplinary tumor board decisions. The cumulative impact is not a replacement of clinical expertise but a shift toward more data-enabled decision support, faster triage, and more consistent interpretation. Responsible implementation depends on transparent algorithms, representative training datasets, cybersecurity safeguards, clinician oversight, and evidence that AI tools improve outcomes without widening disparities.

Key Regional Insights for Stomach Cancer Treatment

Asia-Pacific carries a substantial gastric cancer burden, driven in part by high incidence in East Asian countries and established population-level screening practices in selected health systems. Japan and South Korea have long-standing gastric cancer screening programs that support earlier detection and greater use of endoscopic treatment for eligible early-stage disease, while China is expanding cancer control initiatives, endoscopy capacity, molecular diagnostics, and precision oncology capabilities across major urban centers. In North America, stomach cancer is less common than several other malignancies, but treatment is highly influenced by biomarker testing, multidisciplinary care, clinical trial participation, and access to advanced systemic therapies; the United States and Canada emphasize evidence-based guidelines, supportive oncology services, and structured referral pathways. Latin America faces uneven access to early diagnosis, surgical oncology capacity, pathology infrastructure, radiotherapy services, and newer systemic therapies, with Brazil and Mexico serving as important regional centers for oncology service development. Europe demonstrates strong adoption of guideline-based perioperative therapy, centralized cancer pathways, and molecular diagnostics, although variations remain between Western, Southern, Central, and Eastern European systems in reimbursement and specialist access. The Middle East is strengthening oncology infrastructure, particularly in Gulf countries where tertiary cancer centers, digital health programs, and precision medicine initiatives are expanding, while access can vary across lower-resource settings. Africa faces the most pronounced challenges in timely diagnosis, endoscopy availability, pathology capacity, oncology workforce, radiotherapy access, and affordability of treatment, making health system strengthening, early referral pathways, and essential cancer medicine access critical for improving stomach cancer outcomes.

Key Group Insights for Stomach Cancer Treatment

ASEAN countries present a mixed stomach cancer treatment environment, with advanced oncology centers in urban hubs and persistent gaps in rural screening, diagnostic endoscopy, pathology turnaround, and access to biomarker testing. GCC health systems are investing in tertiary cancer centers, digital health infrastructure, specialist oncology services, and national cancer strategies, supporting wider adoption of multidisciplinary stomach cancer care and advanced systemic treatment where clinically indicated. The European Union benefits from coordinated cancer policy frameworks, cross-border research collaboration, cancer registry infrastructure, and established clinical guideline adoption, though differences in reimbursement, diagnostic capacity, workforce availability, and referral pathways affect treatment consistency. BRICS countries collectively represent a broad and diverse gastric cancer care setting, with China and India managing large patient volumes, Brazil and Russia developing specialized oncology networks, and South Africa facing access constraints that reflect wider regional disparities. G7 countries generally show strong availability of advanced diagnostics, specialist surgery, immunotherapy, targeted treatment, supportive care, and clinical research infrastructure, while also facing pressures related to aging populations, treatment affordability, workforce capacity, and equitable access. NATO member countries overlap with many high-income health systems in North America and Europe, where cancer preparedness, medical supply resilience, digital coordination, and cross-institutional collaboration support continuity of complex oncology care, though national policy, reimbursement, and service organization differences continue to shape patient access.

Key Country Insights for Stomach Cancer Treatment

The United States has a highly specialized stomach cancer treatment ecosystem built around multidisciplinary oncology teams, biomarker testing, clinical trials, immunotherapy, targeted therapy, and complex surgical care for eligible patients. Canada emphasizes publicly funded cancer pathways, provincial oncology programs, and guideline-based management, though geography can affect access to specialized surgical, endoscopic, and diagnostic services. Mexico and Brazil continue to strengthen cancer care capacity, with major urban centers offering advanced oncology services while delayed diagnosis, out-of-pocket burden, and uneven access remain important barriers. The United Kingdom applies national cancer pathways and evidence-based assessment for therapy adoption, while Germany and France maintain strong specialist oncology networks, surgical expertise, diagnostic infrastructure, and molecular testing capabilities. Italy and Spain combine guideline-led perioperative treatment, surgical oncology, radiation oncology, and supportive care, with regional variations in access and service delivery. Russia has been expanding oncology modernization initiatives, but regional differences in diagnostic and treatment availability continue to influence care. China is central to global gastric cancer care due to its high disease burden, growing endoscopy network, expanding molecular diagnostics capability, and increasing clinical research activity. India faces significant variation between metropolitan oncology centers and underserved regions, making affordability, early diagnosis, pathology capacity, and specialist access key priorities. Japan and South Korea are distinguished by organized screening experience, high detection of early gastric cancer, advanced endoscopic treatment expertise, and strong surgical quality systems. Australia provides guideline-based multidisciplinary care supported by specialist cancer centers and clinical research networks, with continued attention to access for rural, remote, and Indigenous populations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated stomach cancer care models that connect gastroenterology, pathology, radiology, surgical oncology, medical oncology, radiation oncology, nutrition, rehabilitation, and palliative care from the point of diagnosis. Expanding access to validated biomarker testing is essential for appropriate use of immunotherapy and targeted therapy, particularly in advanced gastric and gastroesophageal junction cancers. Healthcare organizations should invest in endoscopy quality improvement, early referral pathways, standardized staging workups, and rapid pathology reporting to reduce delays and improve treatment selection. Decision-makers should support clinician education on evolving treatment algorithms, toxicity management, molecular interpretation, nutritional assessment, and shared decision-making. Digital infrastructure should be strengthened to enable multidisciplinary tumor boards, real-world evidence generation, treatment adherence monitoring, survivorship planning, and patient navigation. For emerging and resource-constrained settings, practical priorities include increasing endoscopy availability, improving pathology turnaround times, strengthening surgical oncology training, expanding radiotherapy access, and building affordable access pathways for essential systemic therapies. Across all settings, leaders should measure care quality through evidence-based indicators such as time to diagnosis, completeness of staging, biomarker testing rates, treatment completion, postoperative outcomes, symptom control, nutritional status, and patient-reported quality of life.

Research Methodology

This executive summary is developed through a secondary research approach using verified clinical, regulatory, epidemiological, and public health sources. The methodology emphasizes evidence from peer-reviewed medical literature, oncology treatment guidelines, cancer registry publications, public health agency materials, regulatory documents, and consensus recommendations from recognized clinical organizations. Insights are synthesized qualitatively to assess treatment evolution, technology adoption, regional access patterns, and clinical practice implications without using market sizing, market share, or forecasting. Regional, group, and country perspectives are evaluated through the lens of disease burden, screening practices, diagnostic capacity, treatment infrastructure, biomarker testing availability, reimbursement environments, oncology workforce readiness, and health system preparedness. The analysis prioritizes reproducibility, source credibility, clinical relevance, and alignment with current standards of care. Because stomach cancer treatment is rapidly evolving, the interpretation focuses on durable evidence-backed themes such as biomarker-guided therapy, multidisciplinary care, early detection, supportive oncology, and equitable access rather than speculative commercial projections.

Conclusion

Stomach cancer treatment is advancing toward precision, integration, and earlier intervention. Surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, endoscopic procedures, nutritional care, and palliative support are increasingly coordinated through multidisciplinary pathways that reflect tumor stage, molecular profile, patient condition, and health system capacity. Artificial intelligence, molecular diagnostics, and digital care coordination are strengthening the ability to detect disease, personalize therapy, and monitor outcomes, but their value depends on equitable implementation and validated clinical benefit. Regional differences remain substantial, with East Asian screening experience, high-income country access to advanced therapies, and infrastructure gaps in many low- and middle-resource settings shaping treatment realities. The most effective strategies will be those that improve diagnostic accuracy, expand biomarker access, reduce treatment delays, support evidence-based therapy sequencing, strengthen supportive care, and place patient quality of life at the center of care. As scientific evidence continues to mature, the stomach cancer treatment landscape will reward stakeholders that combine innovation with affordability, operational readiness, and measurable clinical impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stomach Cancer Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Chemotherapy
  • 7.2.1. Fluoropyrimidine-Based
  • 7.2.2. Platinum-Based
  • 7.2.3. Taxane-Based
• 7.3. Immunotherapy
• 7.4. Radiotherapy
  • 7.4.1. Brachytherapy
  • 7.4.2. External Beam
• 7.5. Surgery
  • 7.5.1. Partial Gastrectomy
  • 7.5.2. Total Gastrectomy
• 7.6. Targeted Therapy
• 7.7. Supportive & Adjunctive Therapy

8. Stomach Cancer Treatment Market, by Product Type

• 8.1. Introduction
• 8.2. Drugs
  • 8.2.1. Cytotoxic Chemotherapy Drugs
    • 8.2.1.1. Fluoropyrimidines
    • 8.2.1.2. Taxanes
    • 8.2.1.3. Cisplatin
  • 8.2.2. Biologics & Monoclonal Antibodies
  • 8.2.3. Antibody-Drug Conjugates
• 8.3. Medical Device & Equipment
  • 8.3.1. Surgical Products
  • 8.3.2. Endoscopes
  • 8.3.3. Radiation Devices
  • 8.3.4. Pumps & Catheters

9. Stomach Cancer Treatment Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Intravenous
• 9.3. Oral

10. Stomach Cancer Treatment Market, by Stage

• 10.1. Introduction
• 10.2. Stage I
• 10.3. Stage II
• 10.4. Stage III
• 10.5. Stage IV

11. Stomach Cancer Treatment Market, by Indication

• 11.1. Introduction
• 11.2. Gastric Adenocarcinoma
• 11.3. Gastric Lymphoma
• 11.4. Gastroesophageal Junction Adenocarcinoma
• 11.5. Gastric Neuroendocrine Tumors

12. Stomach Cancer Treatment Market, by End User

• 12.1. Introduction
• 12.2. Homecare
• 12.3. Hospitals
• 12.4. Specialty Clinics
• 12.5. Radiation Oncology Centers

13. Stomach Cancer Treatment Market, by Distribution Channel

• 13.1. Introduction
• 13.2. Hospital Pharmacy
• 13.3. Online Pharmacy
• 13.4. Retail Pharmacy

14. Stomach Cancer Treatment Market, by Region

• 14.1. Asia-Pacific
• 14.2. North America
• 14.3. Latin America
• 14.4. Europe
• 14.5. Middle East
• 14.6. Africa

15. Stomach Cancer Treatment Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Stomach Cancer Treatment Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2025
• 17.2. FPNV Positioning Matrix, 2025
• 17.3. Market Concentration Analysis, 2025
  • 17.3.1. Concentration Ratio (CR)
  • 17.3.2. Herfindahl Hirschman Index (HHI)
• 17.4. Recent Developments & Impact Analysis, 2025
• 17.5. Product Portfolio Analysis, 2025
• 17.6. Benchmarking Analysis, 2025

18. Company Profiles

• 18.1. Amgen Inc.
• 18.2. Astellas Pharma Inc.
• 18.3. AstraZeneca PLC
• 18.4. Bayer AG
• 18.5. BeOne Medicines, Ltd.
• 18.6. Boehringer Ingelheim International GmbH
• 18.7. Bristol Myers Squibb Company
• 18.8. Cipla Limited
• 18.9. Daiichi Sankyo Company, Limited
• 18.10. Eisai Co., Ltd.
• 18.11. Eli Lilly and Company
• 18.12. F. Hoffmann-La Roche Ltd.
• 18.13. Gilead Sciences, Inc.
• 18.14. GlaxoSmithKline PLC
• 18.15. Incyte Corporation
• 18.16. Ipsen Pharma
• 18.17. Johnson & Johnson Services Inc.
• 18.18. LES LABORATOIRES SERVIER
• 18.19. Merck & Co., Inc.
• 18.20. Novartis AG
• 18.21. Ono Pharmaceutical
• 18.22. Otsuka Pharmaceutical Co., Ltd.
• 18.23. Pfizer Inc.
• 18.24. Prestige Biopharma
• 18.25. Sanofi S.A.
• 18.26. Sumitomo Pharma Co., Ltd.
• 18.27. Sun Pharmaceuticals Limited
• 18.28. Taiho Pharmaceutical Co., Ltd.
• 18.29. Takeda Pharmaceutical Company Limited
• 18.30. Teva Pharmaceutical Industries Ltd.